The paradox of choice: Navigating Medicare, Medicaid, and rare disease

Being dually eligible for both Medicare and Medicaid seems like the ultimate healthcare safety net. Two insurance programs, more coverage, and more protection sounds fantastic. But in reality, for many people living with rare and chronic diseases, dual eligibility can feel less like a safety net and more like being caught between two systems that don’t work well together.

I currently receive healthcare through traditional Medicare Parts A and B, prescription coverage through Part D, and the Qualified Medicare Beneficiary Program through Medicaid. On paper, this combination is intended to protect medically vulnerable patients from overwhelming healthcare costs. What it doesn’t show is how often patients fall through the cracks between programs.

Recently, my physician prescribed me several pieces of durable medical equipment, including something as simple as a shower chair. Not a cutting-edge treatment or expensive technology, just a basic piece of equipment that would help me bathe safely.

I was informed that the equipment would not be covered because of the specific way my Medicare and Medicaid benefits are structured. Ironically, had I been enrolled differently or had only one of those programs in certain circumstances, coverage may have been available. That contradiction highlights a frustrating reality many dual-eligible patients encounter: Sometimes having more insurance results in fewer practical benefits.

Recommended Reading

May 6, 2026 Columns by Leah Sirota

Guest Voice: Explaining the complexities of life with rare diseases

Another example dates back more than a decade, when I underwent a root canal that was later discovered to be incomplete. A portion of the root had been missed because of its unusual curvature. Since then, the tooth has repeatedly become infected, particularly when I am already sick or experiencing health complications. The infections require antibiotics and are especially concerning given my underlying conditions of angioedema and multiple sclerosis (MS). Because the procedure was considered a “re-treatment” rather than an initial procedure, Medicaid denied coverage. I appealed, citing the recurrent infections and clear medical necessity.

My appeal was denied.

I was informed that I’m not eligible to file an appeal because it’s “not a covered service” — not medically unnecessary or cosmetic, simply excluded.

Impossible choices

These experiences reveal a larger problem for many dual-eligible patients. Traditional Medicare provides access to essential medical care but often leaves significant gaps in areas that directly affect health and quality of life, including dental care, vision services, transportation, food assistance, and certain types of medical equipment.

Many Medicare Advantage plans advertise benefits designed to address those gaps, such as expanded dental and vision coverage, transportation assistance, grocery allowances, and support for daily living needs. For patients living with complex medical conditions on fixed incomes, those benefits can be life-changing. Naturally, I began exploring whether a Medicare Advantage plan might provide the support I was missing.

Then I encountered what may have been the most frustrating obstacle of all.

Like many rare disease patients, I rely on highly specialized physicians. My care team has played a critical role in helping to stabilize my hereditary angioedema and MS. Their expertise is not easily replaced. When I reviewed Medicare Advantage options, I learned that many plans would not allow me to continue receiving care from my specialists because they were outside the plan’s network.

Then came the next blow: The only Medicare Advantage plans that my treating hospital accepts is their in-house Medicare Advantage plan. And — drumroll — they don’t provide coverage to my zip code. Those lines are drawn by Medicare itself, not the hospital. I’ve been a patient there for nearly a decade and live about 60 miles away, in the same state. Yet a line drawn around my zip code determined that I was ineligible.

Now I have to decide: I can keep access to the specialists who understand my rare diseases and have helped preserve my quality of life, or I could gain access to benefits that would help meet basic daily needs. No patient should have to make that choice.

For now, I’ll continue traveling to receive care from physicians I trust because rare disease care is not interchangeable. Expertise matters. Continuity matters. Trust matters. When a condition can become life-threatening, those relationships can mean the difference between stability and crisis.

But patients shouldn’t have to forfeit dental care, medical equipment, transportation assistance, or other essential supports simply to maintain access to the doctors keeping them alive. Rare disease patients already spend enough energy battling the conditions inside our own bodies. We shouldn’t be forced to navigate fragmented insurance systems that require us to choose between specialized medical care and basic support services.

This isn’t just an inconvenience. It is a policy failure. It exposes the disconnect between Medicare, Medicaid, managed care structures, and the realities of living with a medically complex condition. Coverage on paper means little when the care, equipment, and services necessary to live safely remain out of reach. Until policymakers address the gaps between these systems, dual-eligible patients will continue facing impossible choices — not because care doesn’t exist, but because the programs designed to provide it were never built to work together

Note: Angioedema News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Angioedema News or its parent company, Bionews, and are intended to spark discussion about issues pertaining to angioedema.